Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SynapCell has entered into a preclinical epilepsy research agreement with MedGenesis Therapeutix under which they will evaluate MedGenesis' lead product GDNF, in conjucntion with Convection Enhanced Delivery (CED) technology.
Subscribe to our email newsletter
MedGenesis said GDNF has already showed disease-modifying potential in treating parkinson’s disease and now will be evaluated for epilepsy.
SynapCell will provide a detailed review of the effects of GDNF on the frequency and intensity of behavioral and electroencephalographic seizures in the final report.
SynapCell CEO Corinne Roucard said this project falls within the scope of the company’s core business: assessing the efficacy of epilepsy treatments.
"We are now moving ahead with the actual research, which will go on for nine months," Roucard said .